globenewswire

Orrön Energy AB (“Orrön Energy”) publicerar den finansiella rapporten för det andra kvartalet 2025 på onsdagen den 6 augusti 2025 klockan 07.30, vilket följs av en webbpresentation klockan 14.00.

FORM 8.5 (EPT/RI)

The global space debris monitoring and removal market, valued at USD 1.05 billion in 2024, is set to reach USD 2.05 billion by 2033, growing at a 7.8% CAGR. Driven by increased satellite deployments and demand for advanced debris technologies, the market supports sustainability and risk mitigation in space operations.

SHENZHEN, China, July 25, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it is exploring the integration of emerging technologies, particularly quantum computing, into its existing operations. With its expertise in customer engagement and robust data ecosystem, Aurora Mobile believes quantum computing will be a driving force in its future growth and innovation.

On 31 July 2025 Eesti Energia will publish its 2025 Q2 results. Introduction of the results for investors will take place on 31 July at 11:00 London time, 12:00 Frankfurt time and 13:00 Tallinn time.

Eesti Energia avalikustab 31. juulil oma 2025. aasta 2. kvartali majandustulemused ja vahearuande. Tulemusi tutvustav investorikõne toimub 31. juulil kell 13.00 Tallinna aja järgi.

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

Learn about JackBit Casino, named leading Crypto Casino of 2025. Enjoy instant payouts, 6000+ games, live sports betting, 24/7 support, and more. 

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

NEW YORK und MAINZ, Deutschland, 25. Juli 2025 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an LP.8.1 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY^® LP.8.1) der Unternehmen für die aktive Immunisierung zur Vorbeugung von COVID-19 verursacht durch SARS-CoV-2 bei Personen ab 6 Monaten ausgesprochen hat. Die Anpassung basiert auf der Empfehlung der Notfall-Taskforce (Emergency Task Force, „ETF“) der EMA, die vorschlägt, COVID-19-Impfstoffe zu aktualisieren, um die LP.8.1-Variante für die Impfkampagne 2025-2026 abzudecken. Die Notfall-Taskforce erklärte: „Eine Anpassung an LP.8.1 wird dabei helfen, die Wirksamkeit der Impfstoffe gegen das sich fortlaufend weiterentwickelnde SARS-CoV-2 aufrechtzuerhalten.“²